Heart Failure from Diabetes Drugs, Onglyza & Kombiglyze- 1/4/18 LITIGATION UPDATE

Diabetes Drug Lawsuits

The Judicial Panel on Multidistrict Litigation (JPML) announced that it will hear arguments on January 25, 2018 regarding whether to centralize federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). (To review the JPML’s Hearing Session Order click here.)  Saxagliptin is part…

Read More

SGLT2 Diabetes Drugs Associated with Doubled Risk of Dangerous Levels of Acid in Blood

Medical Drug Safety

A cohort study of 140,352 diabetics showed that sodium-glucose cotransporter 2 (SGLT2 inhibitors) diabetes drugs were associated with approximately twice the risk of diabetic ketoacidosis as were dipeptidyl peptidase-4 (DPP4 inhibitors) diabetes drugs according to a recent letter to the New England Journal of Medicine. SGLT2 inhibitors are a class of prescription medicines that are…

Read More